Skip to content

#cell line

4 public questions tagged with this topic.

NIH/3T3 cells are widely used to study:

NIH/3T3 fibroblasts are widely exploited to study cell cycle regulation, contact inhibition, and oncogenic transformation because they retain intact checkpoints and robust growth factor responsiveness. Confluent 3T3 cultures arrest in G0/G1 through Hippo pathway mediated YAP phosphorylation and induction of cyclin-dependent kinase inhibitors. Serum starvation synchronizes cells, and addition of serum containing PDGF, EGF, insulin triggers coordinated re-entry into cell cycle involving Ras-MAPK cascade, PI3K-Akt activation, and induction of immediate-early transcription factors c-fos, c-jun, c-myc within minutes. Introduction of activated oncogenes such as H-RasV12, v-Src, or Raf via transfection breaks contact inhibition producing foci of transformed cells piling up in monolayer, classic transformation assay quantified by focus formation. Their high transfection efficiency, clonal growth, and stable karyotype support stable expression of cell cycle regulators including p21, p27, cyclin D1. Unlike studies of glycosylation requiring CHO cells or apoptosis only models, 3T3 uniquely captures dynamic proliferation control relevant to wound healing and cancer initiation.

Ref: Pardee AB Science 1974 G1 regulation NIH/3T3; Lodish MBoC 8th Ed Contact inhibition and oncogene transformation focus assay.

NIH/3T3 cells are derived from:

NIH/3T3 line derives from Swiss albino mouse embryo fibroblasts harvested at gestational day 16-18 and disaggregated. Name denotes National Institutes of Health and 3-day transfer protocol inoculating 3 x 10^5 cells per dish developed by George Todaro and Howard Green in 1962. By repeated passage at low density, cells overcoming senescence crisis became spontaneously immortalized while maintaining contact inhibition and anchorage dependence, hallmark of non-transformed fibroblasts. Karyotype shows aneuploidy but relatively stable compared to tumor lines, with near 68 chromosomes. 3T3 cells exhibit characteristic spindle shape, alignment in parallel bundles at confluence, and strict dependence on 10% calf serum supplying platelet-derived growth factor and fibroblast growth factor. Derivative lines include 3T3-L1 capable of adipocyte differentiation upon insulin-dexamethasone treatment, and 3T3-Swiss albino subclones varying in transformation sensitivity. Because p53 and Rb remain largely wild-type, 3T3 remains classic system for growth factor and oncogene studies. Genomic sequencing of NIH-3T3 revealed mutations enabling spontaneous immortalization while retaining checkpoint controls. This knowledge strengthens laboratory safety, protocol reproducibility, and regulatory compliance critical for translational research and clinical applications, ensuring reliable data and workforce protection.

Ref: Todaro GJ & Green H J Cell Biol 1963 3T3 embryonic fibroblasts; ATCC CRL-1658 NIH/3T3 origin and contact inhibition.

HeLa cells show which morphology?

HeLa displays epithelial-like morphology reflecting origin from cervical keratinocytes. In vitro, HeLa forms adherent monolayer of polygonal cells with cobblestone pattern, distinct cell borders, prominent nucleoli, and high nuclear to cytoplasmic ratio typical of carcinoma. Cells lack extensive spindle architecture seen in fibroblast-like populations such as NIH-3T3 which grow elongated and align in parallel arrays. HeLa retains some epithelial characteristics including expression of cytokeratins, presence of microvilli on apical surface, and formation of weak tight junctions but fails to develop high transepithelial resistance. Unlike suspension lines such as Jurkat that float as single round cells, HeLa requires substrate attachment for survival and spreads via integrin mediated adhesion. Ease of culture, rapid doubling, and efficient transfection make HeLa model for cell division imaging, membrane trafficking, and virus infection studies. However lack of true barrier formation makes MDCK or Caco-2 preferable for permeability assays requiring polarized monolayers. Genetic engineering using CRISPR-Cas9 in HeLa enables rapid functional studies despite atypical karyotype. This knowledge strengthens laboratory safety, protocol reproducibility, and regulatory compliance critical for translational research and clinical applications, ensuring reliable data and workforce protection.

Ref: ATCC CCL-2 HeLa morphology epithelial-like; Freshney Ch.16 Epithelial vs fibroblast morphology characteristics.

HeLa cells were originally derived from:

HeLa cell line is earliest and most famous continuous human line, established in February 1951 from epithelial cells of cervical adenocarcinoma biopsied from Henrietta Lacks, 31-year-old African-American patient at Johns Hopkins Hospital. Surgeon Howard Jones collected tissue during diagnosis, and George Gey cultured explant demonstrating unprecedented robust growth doubling every 24 hours without feeder cells. Cytogenetic studies reveal hypotriploid chromosome number 76-80 with numerous translocations, and integration of human papillomavirus type 18 genome producing viral oncoproteins E6 degrading tumor suppressor p53 via ubiquitin-mediated proteolysis and E7 inactivating retinoblastoma protein, enabling immortalization. HeLa contributed to development of polio vaccine by Jonas Salk, studies of viral replication, toxicology testing, and cancer research. Ethical controversy regarding informed consent led to establishment of modern biospecimen guidelines. HeLa contamination of other lines discovered by Walter Nelson-Rees highlighted need for short tandem repeat authentication now mandatory. Efforts to repatriate HeLa genome data under controlled access respect privacy while advancing open science. This knowledge strengthens laboratory safety, protocol reproducibility, and regulatory compliance critical for translational research and clinical applications, ensuring reliable data and workforce protection.

Ref: Scherer et al J Exp Med 1953 HeLa cervical carcinoma origin; Skloot The Immortal Life of Henrietta Lacks 2010; ATCC CCL-2 HeLa HPV-18.